Alx oncology announces september investor conference participation

South san francisco, calif., aug. 31, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.
ALXO Ratings Summary
ALXO Quant Ranking